keyword
MENU ▼
Read by QxMD icon Read
search

primary peritoneal cancer

keyword
https://www.readbyqxmd.com/read/29784667/pattern-specific-transcriptomics-identifies-asgr2-as-a-predictor-of-hematogenous-recurrence-of-gastric-cancer
#1
Haruyoshi Tanaka, Mitsuro Kanda, Takashi Miwa, Chie Tanaka, Daisuke Kobayashi, Shinichi Umeda, Masahiro Shibata, Masaya Suenaga, Norifumi Hattori, Masamichi Hayashi, Naoki Iwata, Suguru Yamada, Goro Nakayama, Michitaka Fujiwara, Yasuhiro Kodera
Hematogenous recurrence is a challenging clinical finding that often leads to fatalities of patients with gastric cancer. Therefore, the identification of specific biomarkers and potential therapeutic target molecules for hematogenous recurrence is required to improve the outcomes of these patients. Here, transcriptome and bioinformatics analyses were conducted to uncover candidate molecules differentially expressed in patients with hematogenous recurrence of gastric cancer. One potential candidate identified was asialoglycoprotein receptor 2 (ASGR2) and small interfering RNA (siRNA) experiments were conducted to determine the effect of manipulating ASGR2 expression has on cell phenotypes...
May 21, 2018: Molecular Cancer Research: MCR
https://www.readbyqxmd.com/read/29782365/utilization-of-an-alternative-docetaxel-based-intraperitoneal-chemotherapy-regimen-in-patients-with-ovarian-fallopian-tube-or-primary-peritoneal-carcinoma-a-continued-need-for-ovarian-cancer-patients
#2
David A Becker, Charles A Leath, Christen L Walters-Haygood, Brentley Q Smith, Kerri S Bevis
OBJECTIVE: The objective of this study was to report the tolerability and toxicity of a regimen consisting of intravenous (IV) docetaxel and intraperitoneal (IP) cisplatin and paclitaxel with granulocyte colony-stimulating factor support. MATERIALS AND METHODS: We conducted a retrospective cohort study of patients with surgical stage II-IV epithelial ovarian, fallopian tube or primary peritoneal carcinoma treated with an outpatient IP chemotherapy regimen consisting of docetaxel 75 mg/m IV and cisplatin 75 mg/m IP day 1 followed by paclitaxel 60 mg/m IP day 8 every 21 days...
May 18, 2018: American Journal of Clinical Oncology
https://www.readbyqxmd.com/read/29773661/phase-i-study-of-oncolytic-vaccinia-virus-gl-onc1-in-patients-with-peritoneal-carcinomatosis
#3
Ulrich M Lauer, Martina Schell, Julia Beil, Susanne Berchtold, Ursula Koppenhöfer, Jörg Glatzle, Alfred Königsrainer, Robert Möhle, Dominik Nann, Falko Fend, Christina Pfannenberg, Michael Bitzer, Nisar P Malek
OBJECTIVE: Peritoneal carcinomatosis (PC) is common in advanced tumor stages or disease recurrence arising from gastrointestinal cancers, gynecologic malignancies, or primary peritoneal carcinoma. Since current therapies are mostly ineffective, new thera-peutic approaches are needed. Here, we report on a phase I study designed to assess safety, MTD, and anti-tumor activity of intra-peri-toneal (i.p.) administration of oncolytic vaccinia virus GL-ONC1 in advanced stage PC patients. DESIGN: GL-ONC1 was administered i...
May 17, 2018: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/29770632/impact-of-increased-utilization-of-neoadjuvant-chemotherapy-on-survival-in-patients-with-advanced-ovarian-cancer-experience-from-a-comprehensive-cancer-center
#4
Yong Jae Lee, Young Shin Chung, Jung Yun Lee, Eun Ji Nam, Sang Wun Kim, Sunghoon Kim, Young Tae Kim
OBJECTIVE: The choice between primary debulking surgery (PDS) and neoadjuvant chemotherapy (NAC) in advanced ovarian cancer remains controversial. We evaluated NAC use in our center before and after results from a randomized trial were published, with the aim to determine the impact of changes in the neoadjuvant strategy on survival in advanced-stage ovarian cancer. METHODS: We retrospectively investigated the clinical course of 435 patients with ovarian, tubal, or peritoneal carcinoma (International Federation of Gynecology and Obstetrics [FIGO] stage III or IV)...
April 18, 2018: Journal of Gynecologic Oncology
https://www.readbyqxmd.com/read/29770618/peritoneal-cancer-index-as-a-predictor-of-survival-in-advanced-stage-serous-epithelial-ovarian-cancer-a-prospective-study
#5
Alaa A Elzarkaa, Waleed Shaalan, Doaa Elemam, Hassan Mansour, Mahmoud Melis, Eduard Malik, Amr A Soliman
OBJECTIVE: A numerical score, the peritoneal cancer index (PCI), was developed to reflect the extent of tumor growth in gastric and colorectal cancers and to tailor treatment. This study aimed to examine the value of the PCI score in advanced epithelial ovarian cancer (EOC) regarding completeness of surgical cytoreduction and survival. METHODS: This was a prospective observational cohort study. Patients with primary serous EOC at International Federation of Gynecology and Obstetrics (FIGO) stages IIIB or higher were included...
March 8, 2018: Journal of Gynecologic Oncology
https://www.readbyqxmd.com/read/29767688/safety-and-dose-modification-for-patients-receiving-niraparib
#6
J S Berek, U A Matulonis, U Peen, P Ghatage, S Mahner, A Redondo, A Lesoin, N Colombo, I Vergote, O Rosengarten, J Ledermann, M Pineda, S Ellard, J Sehouli, A Gonzalez-Martin, D Berton-Rigaud, R Madry, A Reinthaller, S Hazard, W Guo, M R Mirza
Background: Niraparib is a poly(ADP-ribose) polymerase (PARP) inhibitor approved in the United States and Europe for maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy. In the pivotal ENGOT-OV16/NOVA trial, the dose reduction rate due to TEAE was 68.9%, and the discontinuation rate due to TEAE was 14.7%, including 3.3% due to thrombocytopenia. A retrospective analysis was performed to identify clinical parameters that predict dose reductions...
May 14, 2018: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/29767252/colony-stimulating-factor-1-and-colony-stimulating-factor-1-receptor-co-expression-is-associated-with-disease-progression-in-gastric-cancer
#7
Yoshinaga Okugawa, Yuji Toiyama, Takashi Ichikawa, Mikio Kawamura, Hiromi Yasuda, Hiroyuki Fujikawa, Susumu Saigusa, Masaki Ohi, Toshimitsu Araki, Koji Tanaka, Yasuhiro Inoue, Motoyoshi Tanaka, Chikao Miki, Masato Kusunoki
Colony‑stimulating‑factor‑1 (CSF‑1) is a hematopoietic growth factor that exerts its effects through the c‑fms/CSF‑1 receptor (CSF‑1R). The CSF‑1/CSF‑1R axis is thought to be involved in the development of several types of cancer. This study aimed to clarify the clinical and biological significance of the CSF‑1/CSF‑1R axis in gastric cancer (GC). For this purpose, we evaluated CSF‑1 and CSF‑1R expression in GC tissues from 148 patients by RT‑qPCR and immunohistochemistry. The biological roles of the CSF‑1/CSF‑1R axis were investigated by measuring the cell proliferation and migration, and anoikis resistance in a human GC cell line following treatment with recombinant human CSF‑1 and/or CSF‑1R inhibitor...
May 16, 2018: International Journal of Oncology
https://www.readbyqxmd.com/read/29766314/metastatic-colon-cancer-derived-from-a-diverticulum-incidentally-found-at-herniorrhaphy-a-case-report
#8
Jiro Kimura, Alan Kawarai Lefor, Shota Fukai, Kentaro Yoshikawa, Shingo Sasamatsu, Takashi Sakamoto, Ken Mizokami, Masaki Kanzaki, Tadao Kubota, Akira Saito, Hiroshi Izumi, Kunpei Honjo, Kunihiko Nagakari, Masaki Fukunaga
BACKGROUND: There are few reports of metastases from colon cancer to an inguinal hernia sac, and few reports of colon cancer originating in diverticula. We report a patient with carcinoma of the sigmoid colon arising in two diverticula, who presented with peritoneal seeding to an inguinal hernia sac, and a review of the literature. CASE PRESENTATION: A 55-year-old male underwent open herniorrhaphy for a left inguinal hernia. At operation, a nodule in the inguinal hernia sac was resected and histologic examination revealed adenocarcinoma, which was suspected to be a metastasis from a distant primary lesion...
May 15, 2018: Surgical Case Reports
https://www.readbyqxmd.com/read/29761503/evaluation-of-the-peritoneal-surface-disease-severity-score-psdss-in-ovarian-cancer-patients-undergoing-cytoreductive-surgery-and-hipec-two-pathogenetic-types-based-study
#9
Roman Yarema, Taras Fetsych, Natalya Volodko, Myron Оhorchak, Orest Petronchak, Roman Huley, Yuriy Mylyan, Olivier Glehen
BACKGROUND AND OBJECTIVES: Clinical experience suggests that cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) play an important role in the management of ovarian cancer. In order to improve patient selection, the peritoneal surface disease severity score (PSDSS) was previously introduced for use in colorectal cancer patients. However, almost no data exist regarding the utility of the PSDSS index in ovarian cancer patients. METHODS: A retrospective study of the effectiveness of CRS and HIPEC was carried out in 59 patients with ovarian cancer...
May 14, 2018: Journal of Surgical Oncology
https://www.readbyqxmd.com/read/29755913/concurrent-chemoradiation-affects-the-clinical-outcome-of-small-bowel-complications-following-pelvic-irradiation-prospective-observational-study-from-a-regional-cancer-center
#10
Velagala Jayapala Reddy, Sathasivam Sureshkumar, Chellappa Vijayakumar, Anandhi Amaranathan, Sundaramurthi Sudharsanan, Prem Shyama, Chinnakali Palanivel
Background To appraise the spectrum of small bowel complications following pelvic irradiation and to assess the clinical outcome and factors associated with adverse clinical outcome in these patients. Methods This descriptive clinical study was done for three years in a tertiary care center in South India. Patients managed for post-irradiation small bowel complications, irrespective of the indication for radiotherapy, were studied. Patients with associated non-gastrointestinal radiation toxicity, radiation proctitis, and radiation colitis were excluded...
March 13, 2018: Curēus
https://www.readbyqxmd.com/read/29755773/early-experience-with-cytoreduction-and-hyperthermic-intraperitoneal-chemotherapy-at-a-newly-developed-center-for-peritoneal-malignancy
#11
Whitney L Guerrero, Gitonga Munene, Paxton V Dickson, Dina Darby, Andrew M Davidoff, Michael G Martin, Evan S Glazer, David Shibata, Jeremiah L Deneve
Background: Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) has improved outcomes for patients with peritoneal carcinomatosis (PC). We present our experience from a newly developed peritoneal surface malignancy program. Methods: An IRB approved retrospective review was performed for the first 50 patients treated with CRS/HIPEC with clinicopathologic data described. Results: Patients treated with CRS/HIPEC were Caucasian (64%), female (66%) with a median age of 53 years (range, 11-73 years)...
April 2018: Journal of Gastrointestinal Oncology
https://www.readbyqxmd.com/read/29749431/expression-of-annexin-ii-and-stromal-tenascin-c-promotes-epithelial-to-mesenchymal-transition-and-correlates-with-distant-metastasis-in-pancreatic-cancer
#12
Naoko Yoneura, Shigetsugu Takano, Hideyuki Yoshitomi, Yasuyuki Nakata, Reiri Shimazaki, Shingo Kagawa, Katsunori Furukawa, Tsukasa Takayashiki, Satoshi Kuboki, Masaru Miyazaki, Masayuki Ohtsuka
The interaction between cancer cells and stromal components contributes to cancer invasion and metastasis in pancreatic ductal adenocarcinoma (PDAC). The present study investigated the role of the correlation between annexin II (ANX2) and stromal tenascin C (TNC) with the progression of PDAC. The functions of the expression ANX2 and TNC were assessed in in vitro experiments using mouse and human PDAC cells, and the clinical effect was analyzed using immunohistochemistry with surgically resected PDAC tissues...
May 2, 2018: International Journal of Molecular Medicine
https://www.readbyqxmd.com/read/29746229/phase-iii-trial-comparing-intraperitoneal-and-intravenous-paclitaxel-plus-s-1-versus-cisplatin-plus-s-1-in-patients-with-gastric-cancer-with-peritoneal-metastasis-phoenix-gc-trial
#13
Hironori Ishigami, Yoshiyuki Fujiwara, Ryoji Fukushima, Atsushi Nashimoto, Hiroshi Yabusaki, Motohiro Imano, Haruhiko Imamoto, Yasuhiro Kodera, Yoshikazu Uenosono, Kenji Amagai, Shigenori Kadowaki, Hiroto Miwa, Hironori Yamaguchi, Takuhiro Yamaguchi, Tempei Miyaji, Joji Kitayama
Purpose Intraperitoneal paclitaxel plus systemic chemotherapy demonstrated promising clinical effects in patients with gastric cancer with peritoneal metastasis. We aimed to verify its superiority over standard systemic chemotherapy in overall survival. Patients and Methods This randomized phase III trial enrolled patients with gastric cancer with peritoneal metastasis who had received no or short-term (< 2 months) chemotherapy. Patients were randomly assigned at a two-to-one ratio to receive intraperitoneal and intravenous paclitaxel plus S-1 (IP; intraperitoneal paclitaxel 20 mg/m2 and intravenous paclitaxel 50 mg/m2 on days 1 and 8 plus S-1 80 mg/m2 per day on days 1 to 14 for a 3-week cycle) or S-1 plus cisplatin (SP; S-1 80 mg/m2 per day on days 1 to 21 plus cisplatin 60 mg/m2 on day 8 for a 5-week cycle), stratified by center, previous chemotherapy, and extent of peritoneal metastasis...
May 10, 2018: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/29744626/successful-abdominal-wound-closure-for-treatment-of-severe-peritonitis-using-negative-pressure-wound-therapy-with-continuous-mesh-fascial-traction-a-case-report
#14
Hideki Kogo, Jun Hagiwara, Shiei Kin, Eiji Uchida
BACKGROUND: Surgery for severe peritonitis often entails difficult wound closure and may require open abdominal management due to gut edema and/or concern of abdominal compartment syndrome. Negative pressure wound therapy (NPWT) is known to have good outcomes for wound closure after surgery for severe peritonitis. NPWT with continuous mesh fascial traction may result in even better outcomes, especially for fascial closure. CASE PRESENTATION: An 81-year-old man was hospitalized for abdominal pain...
May 9, 2018: Surgical Case Reports
https://www.readbyqxmd.com/read/29743567/mir-338-3p-functions-as-a-tumor-suppressor-in-gastric-cancer-by-targeting-ptp1b
#15
Feng Sun, Mengchao Yu, Jing Yu, Zhijian Liu, Xinyan Zhou, Yanqing Liu, Xiaolong Ge, Haidong Gao, Mei Li, Xiaohong Jiang, Song Liu, Xi Chen, Wenxian Guan
Gastric cancer (GC) is one of the most common malignant tumors and peritoneal metastasis is the primary cause for advanced GC's mortality. Protein-tyrosine phosphatase 1B (PTP1B) functions as an oncogene and involves in carcinogenesis and cancer dissemination. However, the function and regulation of PTP1B in GC remain poorly understood. In this study, we found that PTP1B was upregulated in GC tissues and overexpression of PTP1B in vitro promoted cell migration and prevented apoptosis. Then, we predicted that PTP1B was a target of miR-338-3p and we revealed an inverse correlation between miR-338-3p levels and PTP1B protein levels in GC tissues...
May 9, 2018: Cell Death & Disease
https://www.readbyqxmd.com/read/29743140/a-phase-i-single-arm-open-label-dose-escalation-study-of-intraperitoneal-cisplatin-and-doxorubicin-in-patients-with-recurrent-ovarian-cancer-and-peritoneal-carcinomatosis
#16
Clemens B Tempfer, Urs Giger-Pabst, Veronika Seebacher, Miriam Petersen, Askin Dogan, Günther A Rezniczek
OBJECTIVE: We performed a phase I, single-arm, non-randomized, open-label, dose-escalation trial to determine the dose-limiting toxicity of intraperitoneal cisplatin and doxorubicin applied as pressurized intraperitoneal aerosol chemotherapy (PIPAC) in women with recurrent ovarian cancer. METHODS: We used a standard 3 + 3 dose-escalation design with doxorubicin 1.5 mg/m2 , cisplatin 7.5 mg/m2 q 4 to 6 weeks for 3 cycles and subsequent dose escalation steps (20% increment per step) in patients with recurrent ovarian cancer and peritoneal carcinomatosis...
May 6, 2018: Gynecologic Oncology
https://www.readbyqxmd.com/read/29741294/synaptotagmin-xiii-expression-and-peritoneal-metastasis-in-gastric-cancer
#17
M Kanda, D Shimizu, H Tanaka, C Tanaka, D Kobayashi, M Hayashi, H Takami, Y Niwa, S Yamada, T Fujii, H Sugimoto, Y Kodera
BACKGROUND: Peritoneal metastasis is a frequent cause of death in patients with gastric cancer. The aim of this study was to identify molecules responsible for mediating peritoneal metastasis of gastric cancer. METHODS: Transcriptome and bioinformatics analyses were conducted to identify molecules associated with peritoneal metastasis. The therapeutic effects of intraperitoneally administered small interfering (si) RNA were evaluated using mouse xenograft models...
May 9, 2018: British Journal of Surgery
https://www.readbyqxmd.com/read/29739622/phase-ii-study-of-single-agent-cabozantinib-in-patients-with-recurrent-clear-cell-ovarian-primary-peritoneal-or-fallopian-tube-cancer-nrg-gy001
#18
Panagiotis A Konstantinopoulos, William E Brady, John Farley, Amy Armstrong, Denise S Uyar, David M Gershenson
OBJECTIVE: To evaluate the efficacy and tolerability of cabozantinib in recurrent clear cell ovarian, primary peritoneal or fallopian tube cancer. METHODS: Patients with recurrent ovarian, fallopian or primary peritoneal tumors with at least 50% clear cell histomorphology, measurable disease, one or two prior regimens and ECOG performance status 0-2 received cabozantinib 60 mg orally once daily continuously, in 4-week cycles until disease progression or unacceptable toxicity...
May 5, 2018: Gynecologic Oncology
https://www.readbyqxmd.com/read/29732979/cold-physical-plasma-treated-buffered-saline-solution-as-effective-agent-against-pancreatic-cancer-cells
#19
Sander Bekeschus, Andre Kading, Tim Schroder, Kristian Wende, Christine Hackbarth, Kim Rouven Liedtke, Julia van der Linde, Thomas von Woedtke, Claus-Dieter Heidecke, Lars-Ivo Partecke
Cold physical plasma has been suggested as a new anticancer tool recently. However, direct use of plasma is limited to visible tumors and in some clinical situations not feasible. This includes repetitive treatment of peritoneal metastases which commonly occur in advanced gastrointestinal cancer and in pancreatic cancer in particular. In case of diffuse intraperitoneal metastatic spread Hyperthermic Intraperitoneal Intraoperative Chemotherapy (HIPEC) is used as therapeutic approach. Plasma treated solutions may combine their suspected systemic non-toxic characteristics with the anticancer effects of HIPEC...
May 7, 2018: Anti-cancer Agents in Medicinal Chemistry
https://www.readbyqxmd.com/read/29730071/predictive-factors-of-synchronous-colorectal-peritoneal-metastases-development-of-a-nomogram-and-study-of-its-utilities-using-decision-curve-analysis
#20
Shaobo Mo, Weixing Dai, Wenqiang Xiang, Qingguo Li, Renjie Wang, Guoxiang Cai
BACKGROUND: The objective of this study was to summarize the clinicopathological and molecular features of synchronous colorectal peritoneal metastases (CPM). We then combined clinical and pathological variables associated with synchronous CPM into a nomogram and confirmed its utilities using decision curve analysis. MATERIALS AND METHODS: Synchronous metastatic colorectal cancer (mCRC) patients who received primary tumor resection and underwent KRAS, NRAS, and BRAF gene mutation detection at our center from January 2014 to September 2015 were included in this retrospective study...
May 3, 2018: International Journal of Surgery
keyword
keyword
63801
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"